aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
29 janv. 2025 08h00 HE
|
aTyr Pharma, Inc.
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025...
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
07 nov. 2024 16h01 HE
|
aTyr Pharma, Inc.
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
08 oct. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
02 oct. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
13 août 2024 16h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
22 juil. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
03 juin 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
15 mai 2024 07h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
14 mai 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
02 mai 2024 16h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma announces first quarter 2024 results and provides corporate update